Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis-Reference-Cited by-同舟云学术

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis

Published:2020-08-07 Issue:4 Volume:62 Page:509-515
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle Nerve

Author:

Dyck P. James B.¹^ORCID,Coelho Teresa²,Waddington Cruz Marcia³,Brannagan Thomas H.⁴,Khella Sami⁵,Karam Chafic⁶,Berk John L.⁷,Polydefkis Michael J.⁸,Kincaid John C.⁹,Wiesman Janice F.¹⁰,Litchy William J.¹,Mauermann Michelle L.¹,Ackermann Elizabeth J.¹¹,Baker Brenda F.¹²,Jung Shiangtung W.¹²,Guthrie Spencer¹³,Pollock Michael¹⁴,Dyck Peter J.¹

Affiliation:

1. Department of Neurology Mayo Clinic Rochester Minnesota USA

2. Department of Neurosciences Centro Hospitalar do Porto Porto Portugal

3. Department of Neurology Federal University of Rio de Janeiro, University Hospital Rio de Janeiro Brazil

4. Department of Peripheral Neuropathy Columbia University Medical Center New York New York USA

5. Department of Neurology University of Pennsylvania Philadelphia Pennsylvania USA

6. Department of Neurology Oregon Health & Science University Portland Oregon USA

7. Department of Medicine Boston University Boston Massachusetts USA

8. Department of Neurology Johns Hopkins University Baltimore Maryland USA

9. Department of Neurology Indiana University Indianapolis Indiana USA

10. Department of Neurology New York University New York New York USA

11. Otonomy, Inc San Diego California USA

12. Ionis Pharmaceuticals, Inc. Carlsbad California USA

13. Aurora Bio San Francisco California USA

14. Akcea Therapeutics, Inc. Boston Massachusetts USA

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Clinical Neurology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27023

Reference14 articles.

1. “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy

2. The molecular biology and clinical features of amyloid neuropathy

3. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

4. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy;JAMA;2023-10-17

2. Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis;Cells;2023-09-29

3. Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review;Pharmaceutics;2023-05-30

4. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen;Neurology and Therapy;2022-12-16

5. Long‐term treatment effects of inotersen on health‐related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open‐label extension of the NEURO‐TTR trial;Muscle & Nerve;2022-08-04